Danaher Corporation $DHR Shares Bought by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. boosted its stake in shares of Danaher Corporation (NYSE:DHR) by 6.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 158,784 shares of the conglomerate’s stock after buying an additional 9,891 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Danaher were worth $31,366,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Nuveen LLC acquired a new position in shares of Danaher in the 1st quarter valued at $833,941,000. Invesco Ltd. lifted its stake in shares of Danaher by 44.5% in the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock valued at $965,259,000 after purchasing an additional 1,450,703 shares during the last quarter. Baird Financial Group Inc. lifted its stake in shares of Danaher by 290.6% in the 1st quarter. Baird Financial Group Inc. now owns 1,441,706 shares of the conglomerate’s stock valued at $295,550,000 after purchasing an additional 1,072,617 shares during the last quarter. Generation Investment Management LLP lifted its stake in Danaher by 33.2% during the 1st quarter. Generation Investment Management LLP now owns 3,178,124 shares of the conglomerate’s stock worth $651,515,000 after acquiring an additional 791,662 shares in the last quarter. Finally, Parnassus Investments LLC lifted its stake in Danaher by 23.3% during the 1st quarter. Parnassus Investments LLC now owns 3,828,024 shares of the conglomerate’s stock worth $784,745,000 after acquiring an additional 722,636 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Trading Up 0.1%

NYSE:DHR opened at $223.03 on Friday. The stock’s 50 day moving average price is $202.73 and its 200 day moving average price is $198.53. The company has a market capitalization of $157.54 billion, a PE ratio of 45.99, a P/E/G ratio of 3.41 and a beta of 0.77. The company has a quick ratio of 1.22, a current ratio of 1.52 and a debt-to-equity ratio of 0.33. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $258.23.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, October 21st. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The firm had revenue of $6.05 billion for the quarter, compared to the consensus estimate of $6 billion. During the same quarter last year, the business posted $1.71 EPS. The firm’s quarterly revenue was up 4.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, research analysts anticipate that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, September 26th. Danaher’s dividend payout ratio (DPR) is presently 26.39%.

Insiders Place Their Bets

In other Danaher news, Director Teri List sold 2,778 shares of the stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director directly owned 20,751 shares of the company’s stock, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 11.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on DHR shares. TD Cowen upped their price target on Danaher from $250.00 to $260.00 and gave the stock a “buy” rating in a report on Wednesday. Evercore ISI upped their price target on Danaher from $226.00 to $245.00 and gave the stock an “outperform” rating in a report on Tuesday, October 7th. Robert W. Baird set a $247.00 price target on Danaher in a report on Wednesday. Royal Bank Of Canada set a $241.00 price objective on Danaher in a report on Tuesday, September 2nd. Finally, Guggenheim reiterated a “buy” rating and issued a $250.00 price objective on shares of Danaher in a report on Wednesday, July 23rd. Eighteen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, Danaher currently has an average rating of “Moderate Buy” and an average price target of $243.39.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.